Equity |
6 Months Ended |
---|---|
Jun. 30, 2023 | |
Equity [Abstract] | |
Equity | Note 8 – Equity
Our authorized capital stock consists of an aggregate of 4,505,000,000 shares, comprised of shares of common stock, par value $ per share, and shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of June 30, 2023, we have shares of common stock and shares preferred shares issued and outstanding.
Our non-contrilling interest’s authorized capital stock consists of an aggregate of 505,000,000 shares, comprised of shares of common stock, par value $ per share, and shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of June 30, 2023, we have shares of common stock and shares preferred shares issued and outstanding. In 2022, we issued shares of common stock for an investment in the Company’s Private Placement of $445,000.
In 2022, we issued shares of common stock, valued at $691,520 for consulting services.
In 2022, we committed to issue 18,000 for consulting services, which were issued on January 3, 2023. shares of common stock, valued at $
In 2022, we issued 67,399 for salaries. shares of common stock, valued at $
In 2022, we issued 3,107,570 for a license. shares of common stock, valued at $
In 2022, we issued 242,320 for prepaid fees. shares of common stock, valued at $
In 2022, we issued 1,313,772. shares of common stock for the conversion of convertible notes of $
In 2022, we committed to issue 15,000, which were issued on January 3, 2023. shares of common stock for the conversion of convertible notes of $
In 2023, we issued 488,352. shares of common stock for an investment in the Company’s Private Placement of $
In 2023, we issued 79,600 for consulting services. shares of common stock, valued at $
In 2023, we issued 20,000 for salaries. shares of common stock, valued at $
In 2023, we issued 657,719 shares of common stock for the conversion of convertible notes of $
On August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
On August 9, 2022, we issued shares of preferred shares, valued at per share.
During the six months ended June 30, 2023, the Company’s subsidiary, Res Nova Bio, Inc., issued shares of its common stock to third parties which represented 32% ownership of the subsidiary as of June 30, 2023. Net loss attributable to the noncontrolling interest during the six months ended June 30, 2023 was $856, which netted against the value of the non-controlling interest in equity. The allocation of net loss was presented in the consolidated statement of operations.
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023
|